Hims vs Oak: Prices, Programs & Reviews (2026)
Side-by-side comparison updated for 2026. ClearScores, pricing, medications, and ratings compared.
Hims starts at $199/mo and Oak at $119/mo. Both score 80 on our ClearScore, and Oak is the cheaper starting option.
Quick Verdict
Oak is more affordable ($119/mo vs $199/mo)
Hims has higher ratings (4.5/5 vs 4/5)
Oak scores better on value (4.6/5 vs 4.2/5)
Hims
$199/mo
starting price
Polished telehealth platform with compounded semaglutide, great app experience, and strong brand reputation.
Oak
$119/mo
starting price
Compounded semaglutide from $119/mo, tirzepatide from $185/mo. Starting prices confirmed by Oak September 16, 2026; confirm your dose and plan terms.
Hims vs Oak: Full Comparison
| Hims | Oak | |
|---|---|---|
| ClearScore | 80/100 | 80/100 |
| Overall Rating | 4.5/5 ✓ | 4/5 |
| Review Count | 203 ✓ | 0 |
| Starting Price | $199/mo | $119/mo ✓ |
| Medications | Compounded Semaglutide | Compounded Semaglutide, Compounded Tirzepatide ✓ |
| Telehealth | Yes | Yes |
| Insurance | Not accepted | Not accepted |
| HSA/FSA | Accepted | Not accepted |
| Founded | 2017 | 2024 |
| States Served | All 50 states | All 50 states |
Programs & Pricing
Hims Programs
GLP-1 Weight Loss
$199/mo
Medications: Compounded Semaglutide
- Medication
- Clinician Support
- Progress Tracking
- Free Shipping
Oak Programs
Compounded Semaglutide
From $119/mo
Medications: Compounded Semaglutide
- Medication
- Doctor Consultation
- Care Team Support
- Free Shipping
Compounded Tirzepatide
From $185/mo
Medications: Compounded Tirzepatide
- Medication
- Doctor Consultation
- Care Team Support
- Free Shipping
Ratings Breakdown
| Category | Hims | Oak |
|---|---|---|
| Overall | | |
| Value | | |
| Ease of Use | | |
| Support | | |
| Medication Quality | | |
| Results | | |
The Bottom Line
Hims and Oak are closely matched with ClearScores of 80. Oak is more affordable starting at $119/mo compared to $199/mo. For customer support, Hims rates higher (4.4/5). The best choice depends on your priorities, medication preferences, and budget.